Asha Bailey, DO
Nephrology · Columbia, SCNPI 1619156957
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,438 of the $5,085 with a category attached, or 87.3%. It is spread thinly across 29 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.
Across 241 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$719
- Novartis$603
- Amgen$528
- GSK$387
- Mallinckrodt Hospital Products Inc.$352
- Otsuka America Pharmaceutical, Inc.$352
- plus $2K from 23 others
Across 315 payments — averaging $2281.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$256K
- CSL Behring$194K
- AstraZeneca$141K
- Biogen$76K
- Novartis$22K
- Astrazeneca UK Limited$20K
- plus $9K from 1 others
What the payments were for
- Consulting fees$1102%
- Speaking & faculty fees$2004%
- Travel & lodging$1433%
- Food & beverage$4,43887%
- Education$1944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $719 |
| Novartis | 35 | $603 |
| Amgen(2 entities) | 33 | $528 |
| GSK | 17 | $387 |
| Mallinckrodt Hospital Products Inc. | 9 | $352 |
| Otsuka America Pharmaceutical, Inc. | 18 | $352 |
| Vifor Pharma, Inc. | 6 | $294 |
| Calliditas Therapeutics US Inc. | 12 | $284 |
| Fresenius USA Marketing, Inc. | 13 | $218 |
| Mallinckrodt Enterprises LLC | 5 | $162 |
| Abbott | 1 | $133 |
| Akebia Therapeutics Inc | 8 | $133 |
| Aurinia Pharma U.S., Inc. | 6 | $126 |
| Travere Therapeutics, Inc. | 4 | $97 |
| Sunovion Pharmaceuticals Inc. | 10 | $93 |
| Bayer | 5 | $83 |
| Ardelyx, Inc. | 3 | $76 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $69 |
| Novo Nordisk | 3 | $68 |
| OPKO Pharmaceuticals, LLC | 4 | $65 |
| Lundbeck LLC | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Sanofi | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
- CardioMEMS HF System$133
- TERLIVAZ$125
- ACTHAR$121
- BENLYSTA$110
How this compares
$5,085 in reported general payments places this provider in the 75th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 70 | $165,897 |
| FarxigaDapagliflozin Propanediol | 124 | $80,612 |
| JardianceEmpagliflozin | 33 | $28,202 |
| AuryxiaFerric Citrate | 11 | $18,893 |
| EliquisApixaban | 24 | $17,710 |
| ProcritEpoetin Alfa | 25 | $14,407 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $13,374 |
| RetacritEpoetin Alfa-Epbx | 20 | $5,653 |
| Lanthanum Carbonate | 11 | $4,831 |
| Febuxostat | 11 | $1,467 |
| Midodrine Hcl | 19 | $1,143 |
| Bumetanide | 26 | $888 |
| Calcitriol | 62 | $878 |
| Furosemide | 165 | $868 |
| Metoprolol Succinate | 33 | $658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $218 | $165,89770 claims |
| AstraZenecaFarxiga | $719 | $80,612124 claims |
| Boehringer IngelheimJardiance | $16 | $28,20233 claims |
| Akebia Therapeutics IncAuryxia | $133 | $18,89311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Columbia
- Renee EllisColumbia$40K
- Niall McLaughlinColumbia$15K
- Roy MathewColumbia$10K
- Thomas WheelerColumbia$9K
- Rajeev ShenoyColumbia$8K
- Nzisa MutingaColumbia$6K
- Gregory SmithColumbia$4K
- Abdul UsmaniColumbia$4K
- Carl ShealyColumbia$4K
- David ShureColumbia$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.